Toxicity management of angiogenesis inhibitors: resolution of expert panel
Pavel O. Rumiantsev,
Maria I. Volkova,
Sergey O. Podvyaznikov,
Ilya S. Romanov,
Elena K. Shavarova,
Eugenia A. Shatokhina https://doi.org/10.14341/serg20173157-163
Abstract
On 22 June 2017 in St. Petersburg the expert panel was held on the topic “Management of toxicity of angiogenesis inhibitors”, which discussed current issues of systemic therapy of advanced differentiated thyroid cancer resistant to radioactive iodine therapy, advanced kidney cancer and questions of efficacy and safety of new target drugs in the treatment of these diseases. The reports and discussions of experts raised the following questions: 1. Own experience of using lenvatinib in patients with differentiated thyroid cancer refractory to therapy with radioactive iodine and kidney cancer. 2. Profile of efficacy and safety of modern targeted therapy with multikinase inhibitors. 3. Prophylaxis and management of predictable toxicity.
About the Authors
Pavel O. RumiantsevMaria I. Volkova
Oncology Research Centre named after N.N. Blokhin
Russian Federation
MD, PhD
Sergey O. Podvyaznikov
Oncology Research Centre named after N.N. Blokhin
Russian Federation
professor, MD, PhD
Ilya S. Romanov
Oncology Research Centre named after N.N. Blokhin
Russian Federation
MD, PhD
Elena K. Shavarova
Peoples Friendship University of Russia
Russian Federation
MD, PhD
Eugenia A. Shatokhina
Central State Medical Academy of the President of Russian Federation
Russian Federation
MD, PhD
References
1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Thyroid Carcinoma. Fort Washington; 2017.
2. Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В., и др. Практические рекомендации по лечению злокачественных опухолей головы и шеи. // Злокачественные опухоли. – 2016. – №4s2. – С. 55–63. [Bolotina LV, Vladimirova LY, Den'gina NV, et al. Prakticheskierekomendatsii po lecheniyu zlokachestvennykh opukholey golovy i shei. Zlokachestvennye opukholi. 2016;(4s2):55-63. (In Russ.)] doi: 10.18027/2224-5057-2016-4s2-55-63.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. Fort Washington; 2017.
4. Министерство здравоохранения Российской Федерации. Рак паренхимы почки у взрослых. Клинические рекомендации. 2016. [Ministry of Health of the Russian Federation. Rak parenkhimy pochki u vzroslykh. Clinical guidelines. 2016. (In Russ.)]
5. rlsnet.ru [интернет]. Инструкция по медицинскому применению препарата Ленвима. [доступ от 29.11.2017]. Доступ по ссылке https://www.rlsnet.ru/tn_index_id_87756.htm. [rlsnet.ru [Internet]. Instructions for the medical use of Lenvima. Available from: https://www.rlsnet.ru/tn_index_id_87756.htm. Accessed on 29.11.2017. (In Russ.)]
6. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621-630. doi: 10.1056/NEJMoa1406470.
7. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473-1482. doi: 10.1016/s1470-2045(15)00290-9.
8. Кобалава Ж.Д., Шаварова Е.К. Артериальная гипертония на фоне терапии онкологических заболеваний ингибиторами ангиогенеза: серьезное препятствие или управляемая реакция? // Опухоли головы и шеи. – 2017. – Т. 7. – №2. – С. 70–80. [Kobalava ZD, ShavarovaEK. Arterial hypertension during therapy of oncological diseases with angiogenesis inhibitors: serious impediment or controlled reaction? Head and neck tumors. 2017;7(2):70-80. (In Russ.)] doi: 10.17650/2222 -1468-2017-7-2-70-80.
9. Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-2801. doi: 10.1093/eurheartj/ehw211.
10. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102(9):596-604. doi: 10.1093/jnci/djq091.
11. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation. 2011; 124(15):1687-1691. doi: 10.1161/CIRCULATIONAHA.110.992230.
12. Hayman SR, Leung N, Grande JP, Garovic VD. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep. 2012;14(4):285-294. doi: 10.1007/s11912-012-0242-z.
13. Zerbini G, Lorenzi M, Palini A. Tumor angiogenesis. N Engl J Med. 2008;359(7):763; author reply 764. doi: 10.1056/NEJMc081278.
14. Mir O, Ropert S, Alexandre J, Goldwasser F. Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol. 2009;20(5):967-970. doi: 10.1093/annonc/mdp206.
15. Васильева О.В. Ангиогенные факторы в коже человека в возрастном аспекте: Дис. … канд. мед. наук. – Чебоксары; 2015. [Vasil'eva OV. Аngiogennye faktory v kozhe cheloveka v vozrastnom aspekte. [dissertation] Cheboksary; 2015. (In Russ.)]
16. Thomas JL, Baker K, Han J, et al. Interactions between VEGFR and Notch signaling pathways in endothelial and neural cells. Cell Mol Life Sci. 2013;70(10):1779-1792. doi: 10.1007/s00018-013-1312-6.
17. Sorrell M, Caplan AI. Fibroblasts – a diverse population at the center of it all. Int Rev Cell Mol Biol. 2009;276:161-214. doi: 10.1016/S1937-6448(09)76004-6.
18. Зорина А.И., Зорин В.Л., Черкасов В.Р. Дермальные фибробласты: разнообразие фенотипов и физиологических функций, роль в старении кожи. // Эстетическая медицина. – 2012. – Т. 11. – №1. – С. 15–31. [Zorina АI, Zorin VL, Cherkasov VR. Dermal'nyefibroblasty: raznoobrazie fenotipov i fiziologicheskikh funktsij, rol' v starenii kozhi. Esteticheskaya meditsina. 2012;11(1):15-31. (In Russ.)]
19. Greaves NS, Ashcroft KJ, Baguneid M, Bayat A. Current understanding of molecular and cellular mechanisms in fibroplasia and angiogenesis during acute wound healing. J Dermatol Sci. 2013;72(3):206-217. doi: 10.1016/j.jdermsci.2013.07.008.
20. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6(8):465-477. doi: 10.1038/nrclinonc.2009.94.
21. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124. doi: 10.1056/NEJMoa065044.
22. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-1939. doi: 10.1016/s0140-6736(11)61613-9.
23. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814-1823. doi: 10.1056/NEJMoa1510016.
24. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319-328. doi: 10.1016/s0140-6736(14)60421-9.
25. Королева И.А., Болотина Л.В., Гладков О.А., и др. Практические рекомендации по лекарственному лечению дерматологических осложнений противоопухолевой лекарственной терапии. // Злокачественные опухоли: Практические рекомендации RUSSCO. – 2017. – Т. 7. – №3s2. – С. 514–523. [Koroleva IA, Bolotina LV, Gladkov OA, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniyu dermatologicheskikh oslozhneniy protivoopukholevoy lekarstvennoy terapii. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO. 2017;7(3s2):514-523. (In Russ.)] doi: 10.18027/2224-5057-2017-7-3s2-514-523.
Supplementary files
|
|
1. Частота проявлений кожных токсических реакций 3–4-й степени при лечении ингибиторами ангиогенеза, % | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(45KB)
|
Indexing metadata ▾ | |
Review
For citations:
Rumiantsev P.O., Volkova M.I., Podvyaznikov S.O., Romanov I.S., Shavarova E.K., Shatokhina E.A. Toxicity management of angiogenesis inhibitors: resolution of expert panel. Endocrine Surgery. 2017;11(3):157-163. (In Russ.) https://doi.org/10.14341/serg20173157-163
Views:
1363
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
